The FDA has approved Khindivi, the first hydrocortisone oral solution for pediatric adrenal insufficiency, offering precise, ready-to-use dosing for patients aged 5 years and older.
A new policy urges physicians to offer chaperones during adolescent exams, emphasizing shared decision-making and trauma-informed care to support patient comfort and clinician protection.
A randomized trial found that rizatriptan 10 mg did not significantly reduce vertigo or dizziness within 1 hour during vestibular migraine attacks, though some symptom improvements were seen at 24 hours.
The FDA has approved roflumilast (ZORYVE) foam 0.3% for once-daily treatment of plaque psoriasis in patients aged 12 and older, including hard-to-treat scalp and body areas..